⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ABOS News
Acumen Pharmaceuticals, Inc. Common Stock
Form 8-K
sec.gov
ABOS
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights
globenewswire.com
ABOS
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026
globenewswire.com
ABOS
Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery™, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
globenewswire.com
ABOS
Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery™, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
globenewswire.com
ABOS
Form 8-K
sec.gov
ABOS
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio
globenewswire.com
ABOS
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio
globenewswire.com
ABOS
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
globenewswire.com
ABOS
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
globenewswire.com
ABOS